{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=anti-PD-1+antibody&page=4", "query": { "intervention": "anti-PD-1 antibody", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 503, "total_pages": 51, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=anti-PD-1+antibody&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=anti-PD-1+antibody&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-11T04:23:50.265Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02908906", "title": "A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "JNJ-63723283", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 234, "start_date": "2016-11-21", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-08-31", "last_synced_at": "2026-10-11T04:23:50.265Z", "location_count": 2, "location_summary": "St Louis, Missouri • Pittsburgh, Pennsylvania", "locations": [ { "city": "St Louis", "state": "Missouri" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02908906" }, { "nct_id": "NCT03158883", "title": "UCDCC#270: Avelumab and Stereotactic Ablative Radiotherapy in Non-responding and Progressing NSCLC Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Metastatic Non-small Cell Lung Cancer (NSCLC)" ], "interventions": [ { "name": "Avelumab", "type": "DRUG" }, { "name": "Stereotactic ablative radiotherapy (SAR)", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Megan Daly, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2017-05-17", "completion_date": "2020-06-24", "has_results": false, "last_update_posted_date": "2021-10-20", "last_synced_at": "2026-10-11T04:23:50.265Z", "location_count": 1, "location_summary": "Sacramento, California", "locations": [ { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03158883" }, { "nct_id": "NCT01176474", "title": "Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma (Skin)" ], "interventions": [ { "name": "NY-ESO-1 157-165 (165V)", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "gp100:280-288 (288V)", "type": "BIOLOGICAL" }, { "name": "Montanide ISA 51 vegetable grade (VG)", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Apheresis Procedure", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 73, "start_date": "2010-08-13", "completion_date": "2023-01-06", "has_results": false, "last_update_posted_date": "2023-07-19", "last_synced_at": "2026-10-11T04:23:50.265Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01176474" }, { "nct_id": "NCT05034536", "title": "PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Melanoma" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Infliximab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Relatlimab", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2022-02-07", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-08-24", "last_synced_at": "2026-10-11T04:23:50.265Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05034536" }, { "nct_id": "NCT02399371", "title": "Pembrolizumab in Treating Patients With Malignant Mesothelioma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Biphasic Mesothelioma", "Epithelioid Mesothelioma", "Peritoneal Malignant Mesothelioma", "Pleural Biphasic Mesothelioma", "Pleural Epithelioid Mesothelioma", "Pleural Malignant Mesothelioma", "Pleural Sarcomatoid Mesothelioma", "Recurrent Peritoneal Malignant Mesothelioma", "Recurrent Pleural Malignant Mesothelioma", "Sarcomatoid Mesothelioma" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacogenomic Study", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 65, "start_date": "2015-03-31", "completion_date": "2026-03-20", "has_results": true, "last_update_posted_date": "2026-05-08", "last_synced_at": "2026-10-11T04:23:50.265Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02399371" }, { "nct_id": "NCT02707666", "title": "A Pilot Window-Of-Opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pleural Mesothelioma" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Cisplatin and Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2016-02-25", "completion_date": "2023-04-24", "has_results": false, "last_update_posted_date": "2024-07-31", "last_synced_at": "2026-10-11T04:23:50.265Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02707666" }, { "nct_id": "NCT01714739", "title": "A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "CANCER,NOS" ], "interventions": [ { "name": "Lirilumab", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 337, "start_date": "2012-10-07", "completion_date": "2019-12-13", "has_results": true, "last_update_posted_date": "2023-02-02", "last_synced_at": "2026-10-11T04:23:50.265Z", "location_count": 16, "location_summary": "San Francisco, California • Ocala, Florida • Chicago, Illinois + 11 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Ocala", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Lutherville", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01714739" }, { "nct_id": "NCT02843165", "title": "Checkpoint Blockade Immunotherapy Combined With Stereotactic Body Radiation in Advanced Metastatic Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Cancer" ], "interventions": [ { "name": "Checkpoint blockade immunotherapy", "type": "DRUG" }, { "name": "Checkpoint blockade immunotherapy plus SBRT", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "University of California, San Diego", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 106, "start_date": "2016-09-02", "completion_date": "2024-08-15", "has_results": true, "last_update_posted_date": "2025-09-30", "last_synced_at": "2026-10-11T04:23:50.265Z", "location_count": 1, "location_summary": "La Jolla, California", "locations": [ { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02843165" }, { "nct_id": "NCT04200963", "title": "A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Urothelial Carcinoma", "Urothelial Carcinoma Bladder", "Bladder Cancer", "Bladder Disease", "Solid Tumor", "Solid Carcinoma", "Solid Tumor, Adult", "Metastatic Cancer", "Advanced Solid Tumor", "Advanced Cancer", "Metastatic Bladder Cancer", "Metastatic Urothelial Carcinoma", "Locally Advanced Solid Tumor", "Neoplasms", "Neoplasm Metastasis", "Neoplasm Malignant", "Neoplasm, Bladder", "Urothelial Neoplasm", "Neoplasm, Urinary Bladder", "Bladder Neoplasm", "Bladder Urothelial Carcinoma" ], "interventions": [ { "name": "IK-175", "type": "DRUG" }, { "name": "IK-175 and nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ikena Oncology", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 78, "start_date": "2019-12-18", "completion_date": "2023-07-18", "has_results": false, "last_update_posted_date": "2024-03-15", "last_synced_at": "2026-10-11T04:23:50.265Z", "location_count": 10, "location_summary": "Gilbert, Arizona • Sarasota, Florida • Chicago, Illinois + 7 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Grand Rapids", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04200963" }, { "nct_id": "NCT04348916", "title": "Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer", "Melanoma", "Solid Tumor", "Squamous Cell Carcinoma of Head and Neck", "Breast Cancer", "Advanced Solid Tumor", "Triple Negative Breast Cancer", "Colorectal Carcinoma", "Non-melanoma Skin Cancer", "Liver Metastases" ], "interventions": [ { "name": "ONCR-177", "type": "BIOLOGICAL" }, { "name": "pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Oncorus, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 66, "start_date": "2020-05-20", "completion_date": "2023-05-31", "has_results": false, "last_update_posted_date": "2023-06-08", "last_synced_at": "2026-10-11T04:23:50.265Z", "location_count": 10, "location_summary": "Duarte, California • Denver, Colorado • Tampa, Florida + 6 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04348916" } ] }